Cargando…

Factors associated with initiation and persistence of urate-lowering therapy

BACKGROUND: Gout is the most common inflammatory arthritic disease and is caused by crystal deposition secondary to persistent hyperuricemia. Etiological treatment with urate-lowering therapy (ULT) has been available since the 1950s but previous studies have demonstrated suboptimal degree of treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dehlin, Mats, Ekström, Emin Hoxha, Petzold, Max, Strömberg, Ulf, Telg, Gunilla, Jacobsson, Lennart T. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240247/ https://www.ncbi.nlm.nih.gov/pubmed/28095891 http://dx.doi.org/10.1186/s13075-016-1211-y

Ejemplares similares

Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy
por: Drivelegka, Panagiota, et al.
Publicado: (2018)

Correction to: Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy
por: Drivelegka, Panagiota, et al.
Publicado: (2018)

Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis—a post-hoc analysis of pooled data from three phase 3 trials with secukinumab
por: Dehlin, Mats, et al.
Publicado: (2021)

Association between serum level of urate and subclinical atherosclerosis: results from the SCAPIS Pilot
por: Drivelegka, Panagiota, et al.
Publicado: (2020)

Association between perinatal factors and future risk for gout—a nested case-control study
por: Dehlin, Mats, et al.
Publicado: (2022)

Association between serum urate and CSF markers of Alzheimer's disease pathology in a population‐based sample of 70‐year‐olds
por: Fatima, Tahzeeb, et al.
Publicado: (2021)

Validity of gout diagnosis in Swedish primary and secondary care - a validation study
por: Dehlin, Mats, et al.
Publicado: (2015)

Persistence with urate‐lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions
por: Coleshill, Matthew J., et al.
Publicado: (2022)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study
por: Dehlin, Mats, et al.
Publicado: (2022)

Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden
por: Landgren, Anton Jonatan, et al.
Publicado: (2021)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
por: Choi, Hyon K., et al.
Publicado: (2022)

Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study
por: Lindström, Ulf, et al.
Publicado: (2016)

Incidence and prevalence of gout in Western Sweden
por: Dehlin, Mats, et al.
Publicado: (2016)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR study
por: Franzén, Stefan, et al.
Publicado: (2016)

Occupational exposure to inorganic dust and risk of gout: a population-based study
por: Sigurdardottir, Valgerdur, et al.
Publicado: (2020)

Gender differences in illness perceptions and disease management in patients with gout, results from a questionnaire study in Western Sweden
por: Bergsten, Ulrika, et al.
Publicado: (2023)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
por: Pang, Lei, et al.
Publicado: (2023)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

Dual energy CT findings in gout with rapid kilovoltage-switching source with gemstone scintillator detector
por: Svensson, Elin, et al.
Publicado: (2020)

The absolute risk of gout by clusters of gout-associated comorbidities and lifestyle factors—30 years follow-up of the Malmö Preventive Project
por: Fatima, Tahzeeb, et al.
Publicado: (2020)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Management and Risk of Mortality in Patients Hospitalised Due to a First Severe COPD Exacerbation
por: Janson, Christer, et al.
Publicado: (2020)

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
por: Mandell, Brian F., et al.
Publicado: (2018)

Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
por: Do, Hyunsue, et al.
Publicado: (2023)

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
por: Janssen, C. A., et al.
Publicado: (2018)

Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort
por: Ranieri, Laura, et al.
Publicado: (2018)

Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus
por: Chang, Hsin-Wen, et al.
Publicado: (2019)

Depressive Symptoms and the Effectiveness of a Urate‐Lowering Therapy in a Clinical Trial
por: Mrug, Sylvie, et al.
Publicado: (2020)

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
por: Tabi-Amponsah, Adwoa Dansoa, et al.
Publicado: (2023)

Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2017)

Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2020)

Review of Urate-Lowering Therapeutics: From the Past to the Future
por: Jenkins, Christopher, et al.
Publicado: (2022)

Overuse of short-acting β(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme
por: Nwaru, Bright I., et al.
Publicado: (2020)

Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden
por: Ekström, Magnus, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3lodgqlpcaj5aaqcdpafvd8th9